Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Asuragen launches new leukemia in vitro diagnostic device
The CE-marked Signature LTx v2.0 is a qualitative in vitro diagnostic (IVD) device for use in a clinical laboratory to identify specific fusion transcripts in total RNA from
The CE-marked Signature LTx v2.0 is a qualitative in vitro diagnostic (IVD) device for use in a clinical laboratory to identify specific fusion transcripts in total RNA from
The results according to the Propel investigators at the time of this analysis showed that 42 of 109 evaluable patients (39%) achieved either a complete or partial response,
If approved, Latisse would be the first and only FDA-approved pharmaceutical to enhance eyelash prominence, the company said. In addition to its unanimous recommendation for approval of Latisse,
According to the company, the patent broadly relates to the administration of compositions containing bacteriophages to individuals colonized with pathogenic bacteria in order to prevent the development of
Pursuant to the terms of the collaboration, Galapagos’s service division, BioFocus DPI, will develop a cell-based assay for Dart Neuroscience’s (DNS’s) drug discovery programs for brain disorders and
Under the extension to the licensing agreement, Palatin will receive an upfront payment of $1.6 million and AstraZeneca has been granted licenses to additional compounds and patents. Additionally,
Under the terms of the agreement, Roche Applied Science will market cell-systems, based on the technology of Axiogenesis Cor.At being customized for the xCELLigence platform. The Roche xCELLigence
The Phase II randomized, double-blind, multi-center trial will evaluate the safety, tolerability and efficacy of an intravenous bolus of PRT060128 followed by one of three doses (50mg, 100mg,
Primary objectives for the dose escalation study include determining the maximum tolerated dose and dose limiting toxicity of ENMD-2076 when administered orally once a day in patients with
Under the terms of the agreement, Galen will pay Stellar an upfront milestone payment plus a specified transfer price in exchange for the rights to an exclusive license